Women's mental health statistics: the anxiety and depression data we should be talking about

A patient of mine once described her depression as a fog that made every task feel like walking through wet concrete. She had been experiencing it since her second pregnancy. By the time she told me, her youngest was three. She had not mentioned it before because she assumed feeling that way was just part of being a mother.

Depression and anxiety are not gender-neutral conditions. Women experience both at significantly higher rates than men, across every age group and in every country where data has been collected. The reasons are partly biological, partly social, and partly systemic. And the treatment gap (the distance between how many women need help and how many receive it) is staggering.

The gender gap in depression

The World Health Organization estimates that depression affects approximately 280 million people worldwide. Women carry a disproportionate share of that burden. Globally, about 5.7% of women are affected by depressive disorders at any given time, compared to 3.6% of men. That roughly 2-to-1 ratio has been documented consistently across decades of epidemiological research.

In the United States, the National Institute of Mental Health reports that 10.3% of adult women experienced at least one major depressive episode in 2021, compared to 6.2% of men. Among women aged 18 to 25, the figure was 18.6% — nearly 1 in 5.

This gender gap emerges at puberty. Before age 12, boys and girls experience depression at roughly equal rates. Between ages 12 and 15, the female-to-male ratio shifts sharply. By adulthood, women are about twice as likely to meet diagnostic criteria for major depressive disorder. The gap persists across the lifespan, narrowing somewhat after menopause but never fully closing.

The National Comorbidity Survey Replication (Kessler et al., 2005) (the largest epidemiological study of mental disorders in the U.S.) found the lifetime prevalence of major depression to be 20.2% for women and 11.1% for men. One in five women will experience major depression at some point in her life.

Anxiety disorders in women

Anxiety disorders are even more common than depression, and the gender disparity is equally pronounced.

Data from the National Comorbidity Survey Replication shows that 23.4% of U.S. women meet lifetime criteria for any anxiety disorder, compared to 14.3% of men. Specific disorders show different patterns:

Anxiety disorder	Lifetime prevalence, women	Lifetime prevalence, men
Generalized anxiety disorder	7.1%	4.2%
Panic disorder	6.2%	3.1%
Social anxiety disorder	13.0%	11.1%
Specific phobias	15.7%	7.9%
PTSD	9.7%	3.6%

Source: Kessler et al., Archives of General Psychiatry, 2005

The PTSD numbers stand out. Women are nearly 3 times as likely as men to develop PTSD. This is driven in part by higher rates of sexual assault and intimate partner violence (experiences that carry particularly high PTSD risk) and in part by sex differences in threat processing and fear conditioning.

Anxiety and depression frequently co-occur. Among women with major depression, roughly 60% also meet criteria for at least one anxiety disorder. The overlap complicates treatment and is associated with worse outcomes, higher disability, and greater resistance to standard first-line therapies.

What the pandemic did

The COVID-19 pandemic did not create the mental health crisis among women. It accelerated it.

A 2021 study published in The Lancet by Santomauro and colleagues analyzed data from 204 countries and estimated that the pandemic increased the global prevalence of major depression by 27.6% and anxiety disorders by 25.6% in 2020 alone. Women bore a larger share of the increase in both conditions.

The mechanisms were not mysterious. Women were more likely to lose employment in service and hospitality sectors. They absorbed a disproportionate increase in caregiving burden when schools and daycare facilities closed. They experienced higher rates of domestic violence during lockdowns. And they were overrepresented in healthcare and essential worker roles that carried sustained stress and trauma exposure.

In the United States, the Census Bureau's Household Pulse Survey tracked mental health indicators in near-real-time during the pandemic. In early 2021, 36% of women aged 18 to 29 reported symptoms consistent with anxiety disorder, compared to 22% of men in the same age group. Among women with children under 12 at home, 49% reported symptoms of anxiety or depression, compared to 40% of fathers.

The pandemic-era numbers have improved from their peaks, but they have not returned to pre-2020 baselines. The mental health toll continues to accumulate, particularly among younger women and those in lower-income brackets.

Hormonal links to mood disorders

The 2-to-1 gender ratio in depression is not a social artifact. There is a biological component, and it is linked to reproductive hormones.

The gender gap emerges at puberty and corresponds to the onset of cyclical fluctuations in estrogen and progesterone. Several lines of evidence point to hormonal sensitivity as a contributing factor:

Premenstrual dysphoric disorder (PMDD) affects 3% to 8% of women of reproductive age. It involves severe mood symptoms (irritability, depression, anxiety) tied to the luteal phase of the menstrual cycle. The symptoms resolve with menstruation and are directly mediated by changes in ovarian hormones. PMDD is not "bad PMS" — it is a clinically distinct condition that can be severely disabling. If you experience mood changes tied to your cycle, tracking with a period calculator can help identify patterns.

Perinatal depression affects approximately 1 in 7 women during pregnancy or in the year after childbirth. A Lancet Psychiatry Commission review noted that perinatal depression is one of the most common complications of pregnancy, yet screening and treatment remain inconsistent. The rapid hormonal changes after delivery (estrogen drops by 90% within 48 hours) are a significant trigger in women who are biologically susceptible.

Perimenopausal depression is a recognized clinical entity. The transition to menopause is associated with a 2- to 4-fold increased risk of a new depressive episode, even in women with no prior psychiatric history. Fluctuating and declining estrogen levels during perimenopause are believed to destabilize serotonin signaling in the brain. Our perimenopause article covers the broader symptom picture.

Hormones are not destiny. Social and environmental factors (gender-based violence, caregiving burden, economic inequality, discrimination) all contribute to the gender gap. But the hormonal component is real, well-documented, and clinically relevant for treatment decisions.

The treatment gap

The WHO estimates that globally, 56% of women with depression receive no treatment. In low- and middle-income countries, the treatment gap exceeds 80%. Even in high-income countries, a significant share of women with diagnosable conditions go untreated.

In the United States, data from the National Survey on Drug Use and Health shows that 47.2% of adult women with major depressive episodes received no treatment in the preceding year. "No treatment" means no medication, no therapy, not even a single clinical visit for the condition.

Among women who do receive treatment, antidepressants are the most common modality. A CDC analysis of NHANES data (Brody and Gu, 2020) found that 17.7% of U.S. women reported using antidepressant medication, compared to 8.4% of men. Usage was highest among non-Hispanic white women (22.3%) and lowest among non-Hispanic Asian women (3.4%) and Hispanic women (8.9%).

The disparities in antidepressant use by race do not reflect differences in depression prevalence. They reflect differences in access, provider availability, cultural factors in help-seeking behavior, and the way the healthcare system is structured. Black and Hispanic women are less likely to have access to mental health specialists and more likely to receive mental health care, if any, through primary care or emergency settings.

Psychotherapy access is even more limited. Wait times for a therapist accepting new patients average 25 to 48 days in most U.S. markets. For in-network therapists covered by insurance, waits can exceed 3 months. Teletherapy expanded access during the pandemic but has not eliminated the shortage of licensed providers.

Young women are in crisis

The data on adolescent and young adult women is alarming, and it has been getting worse for a decade.

The CDC's Youth Risk Behavior Survey, which tracks mental health indicators among U.S. high school students, reported in its 2021 data cycle that 57% of girls experienced persistent feelings of sadness or hopelessness (defined as nearly every day for at least 2 weeks), compared to 29% of boys. In 2011, the figure for girls was 36%. That is a 21-percentage-point increase over a decade.

Suicide-related behaviors show a parallel trend. In 2021, 30% of high school girls seriously considered attempting suicide (up from 19% in 2011). Thirteen percent had attempted suicide in the past year. Among LGBTQ+ students, 45% seriously considered suicide.

For young women aged 18 to 25 in the NIMH data, the prevalence of major depressive episodes is 18.6% — the highest of any age-sex group. This is not a small blip. Nearly 1 in 5 young women in the U.S. experienced major depression in 2021.

The causes are debated. Social media exposure, economic anxiety, climate distress, social isolation during the pandemic, and academic pressure all appear in the research literature. What is not debated is the trend. It is steep, it is sustained, and it is disproportionately concentrated among girls and young women.

Race, income, and access

Mental health outcomes are shaped by the same structural factors that drive other health disparities.

Black women are less likely than white women to be diagnosed with depression, even when symptom severity is comparable. This reflects both underdiagnosis by providers and lower rates of help-seeking in clinical settings. When Black women are diagnosed, they are less likely to receive guideline-concordant treatment — meaning appropriate medication dosing, adequate therapy duration, and follow-up care.

Hispanic and Latina women face language barriers, cultural stigma around mental illness, and lower insurance coverage rates that compound the treatment gap. Among immigrant women, fear of immigration enforcement has been documented as a barrier to seeking any form of healthcare, including mental health services.

Income is a consistent predictor. Women living below the federal poverty line have depression rates roughly twice those of women in higher-income brackets. They are simultaneously less likely to have insurance, less likely to live near a mental health provider, and less likely to have the time flexibility to attend regular therapy appointments.

Rural women face a particular version of this problem. The Health Resources and Services Administration has designated more than 6,000 areas in the U.S. as Mental Health Professional Shortage Areas. Many of these are rural counties where the nearest psychiatrist may be hours away.

Economic cost of untreated mental illness

Depression is the leading cause of disability worldwide, per the WHO. The economic costs are immense and fall disproportionately on women.

In the United States, the total economic burden of major depressive disorder is estimated at more than $326 billion annually (Greenberg et al., 2021, Journal of Clinical Psychiatry). This includes direct medical costs, suicide-related costs, and the largest component — workplace costs from absenteeism, presenteeism (working while impaired), and disability.

Women with untreated depression miss an average of 5.6 hours of work per week due to symptoms. Over a year, that accumulates to significant lost income, reduced career advancement, and in some cases, job loss. For women already in lower-paying jobs, the economic hit is proportionally larger.

Treatment is cost-effective. A WHO analysis found that every $1 invested in scaling up treatment for depression and anxiety returns $4 in improved health and productivity. The barrier is not economics. It is will, infrastructure, and the persistent undervaluation of mental health in healthcare budgets.

What effective treatment looks like

Depression and anxiety are treatable conditions. The evidence base for first-line treatments is strong.

For moderate to severe depression, antidepressant medication (SSRIs and SNRIs) produces response rates of 50% to 60% within 6 to 8 weeks. Adding cognitive behavioral therapy (CBT) to medication improves outcomes further. For mild depression, CBT alone is often sufficient.

For anxiety disorders, CBT is the most effective psychotherapy, with response rates of 50% to 75% for generalized anxiety disorder and panic disorder. Exposure-based therapies are particularly effective for phobias and PTSD.

For hormonally linked mood conditions, specific approaches matter. PMDD responds well to SSRIs (which can be taken continuously or only during the luteal phase), and the data supports oral contraceptives containing drospirenone for some women. Perinatal depression should be treated with therapy and, when needed, medication — brexanolone (Zulresso) was the first FDA-approved treatment specifically for postpartum depression, and zuranolone (Zurzuvae), an oral medication, was approved in 2023.

What does not work: telling women to exercise more and think positive. Exercise is beneficial as an adjunct, but it is not a substitute for evidence-based treatment in moderate to severe illness. The tendency to prescribe lifestyle changes in place of actual treatment is a form of dismissal that disproportionately affects women.

For tracking mood patterns alongside your menstrual cycle, our period calculator and guide on late periods can help identify whether hormonal timing plays a role in your symptoms.

Frequently asked questions about women's mental health statistics

Why are women more likely to have depression than men?

Women are approximately twice as likely as men to experience major depression. The WHO reports a prevalence of 5.7% in women versus 3.6% in men globally. The gender gap is driven by a combination of biological factors (hormonal fluctuations during puberty, menstruation, pregnancy, and menopause), psychosocial factors (higher rates of gender-based violence, caregiving burden, economic inequality), and differences in how stress and trauma are processed neurobiologically.

How common is anxiety in women?

Anxiety disorders affect 23.4% of women at some point in their lifetime, compared to 14.3% of men, according to the National Comorbidity Survey Replication. Generalized anxiety disorder, panic disorder, and PTSD all show significant female predominance. Women are nearly 3 times as likely as men to develop PTSD, driven in part by higher rates of sexual violence exposure.

Did the pandemic worsen women's mental health?

Yes. A 2021 Lancet study analyzing 204 countries found that the pandemic increased global depression prevalence by 27.6% and anxiety by 25.6%, with women disproportionately affected. In the U.S., 36% of women aged 18 to 29 reported anxiety disorder symptoms in early 2021. Contributing factors included job loss, increased caregiving, school closures, domestic violence, and healthcare worker stress.

What percentage of women with depression go untreated?

Globally, the WHO estimates that 56% of women with depression receive no treatment. In the United States, 47.2% of adult women with major depressive episodes received no treatment in the preceding year. Treatment gaps are widest among low-income women, women of color, rural women, and women in low- and middle-income countries where the gap exceeds 80%.

Is depression linked to hormones?

Yes. The gender gap in depression emerges at puberty and corresponds to the onset of reproductive hormone cycling. PMDD affects 3% to 8% of women with severe mood symptoms tied to the menstrual cycle. Perinatal depression affects 1 in 7 women. Perimenopause carries a 2- to 4-fold increased risk of new depressive episodes. Estrogen influences serotonin signaling in the brain, and hormonal fluctuations can destabilize mood in susceptible women.

How is depression in women treated differently from men?

Treatment fundamentals (SSRIs, CBT) are the same, but women-specific conditions require tailored approaches. PMDD can be treated with luteal-phase SSRI dosing. Perinatal depression has FDA-approved medications (brexanolone, zuranolone). Perimenopausal depression may respond to hormone therapy in combination with antidepressants. Medication selection also accounts for pregnancy planning, breastfeeding, and hormonal contraceptive interactions that are not relevant in male patients.